Literature DB >> 6749897

Abnormal morphology of bacteria in the sputa of patients treated with antibiotics.

V Lorian, A Waluschka, Y Kim.   

Abstract

Filaments of Klebsiella pneumoniae were observed by Gram stain in the sputum of a patient with a respiratory infection who was treated with half the usual dose of cefazolin. Identical filaments were observed in vitro when this strain was incubated with subminimum inhibitory concentrations of cefazolin. Large gram-positive cocci containing multiple cross walls were observed by electron microscopy in the sputum of a patient with a respiratory infection who was treated with ampicillin and gentamicin. Antibiotic administration was suspended the night before the sputum was obtained. The ultrastructure of these cocci was very similar to the ultrastructure of Staphylococcus aureus incubated with subminimum inhibitory concentrations of cephaloridine or oxacillin. It was suspected that the low dose of cefazolin and the intermittent therapy with ampicillin resulted in a subminimum inhibitory concentration of antibiotic in the respiratory tract which induced the the abnormal morphology of the bacteria observed in the sputum of both patients. The presence of abnormal forms of bacteria in the specimen of a patient, rather than in the culture of a specimen, has clinical significance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6749897      PMCID: PMC272365          DOI: 10.1128/jcm.16.2.382-386.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Blood cultures showing aberrant forms of bacteria.

Authors:  V Lorian; A Waluschka
Journal:  Am J Clin Pathol       Date:  1972-03       Impact factor: 2.493

2.  Aberrant form of Pseudomonas aeruginosa in sputum and cerebrospinal fluid causing infection in a compromised patient.

Authors:  J Middleton; H Chmel
Journal:  J Clin Pathol       Date:  1978-04       Impact factor: 3.411

3.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

4.  Aberrant forms of bacteria and fungi found in blood or cerebrospinal fluid.

Authors:  D B Louria; T Kaminski; M Grieco; J Singer
Journal:  Arch Intern Med       Date:  1969-07

5.  Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12.

Authors:  B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

6.  Effect of serum on gram-positive cocci grown in the presence of penicillin.

Authors:  V Lorian; B Atkinson
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

7.  Interactions between antibiotics and human neutrophils in the killing of staphylococci.

Authors:  R K Root; R Isturiz; A Molavi; J A Metcalf; H L Malech
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

8.  Effects of subinhibitory concentrations of antibiotics on cross walls of cocci.

Authors:  V Lorian; B Atkinson
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

9.  Novel bacterial structures in human blood: cultural isolation.

Authors:  G J Domingue; J U Schlegel
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

10.  Aberrant forms of Escherichia coli in blood cultures: in vitro reproduction of an in vivo observation.

Authors:  C R Magnussen; J F Hruska
Journal:  J Clin Microbiol       Date:  1980-11       Impact factor: 5.948

View more
  13 in total

1.  Utility of gram stain in evaluation of sputa from patients with cystic fibrosis.

Authors:  E Sadeghi; A Matlow; I MacLusky; M A Karmali
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

Review 2.  The necessity to revise Koch's postulates and its application to infectious and non-infectious diseases: a mini-review.

Authors:  Hasan Hosainzadegan; Rovshan Khalilov; Pourya Gholizadeh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-22       Impact factor: 3.267

3.  Phagocytosis of bacterial aggregates by granulocytes.

Authors:  F Galdiero; C Romano Carratelli; I Nuzzo; C Bentivoglio; M Galdiero
Journal:  Eur J Epidemiol       Date:  1988-12       Impact factor: 8.082

4.  Demonstration of pathogenic bacteria in "sterile" inflammatory exudates.

Authors:  R C Bridger
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

5.  Effect of metronidazole on the pathogenicity of resistant Bacteroides strains in gnotobiotic mice.

Authors:  C G Diniz; D C Cara; J R Nicoli; L D Farias; M A De Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Outbreak in African lions of Yersinia pseudotuberculosis infection, with aberrant bacterial morphology.

Authors:  Mandy Womble; Megan L Cabot; Tara Harrison; Tatiane Terumi Negrão Watanabe
Journal:  J Vet Diagn Invest       Date:  2022-01-17       Impact factor: 1.279

7.  Interaction of beta-lactam antibiotics with the bactericidal activity of leukocytes against Escherichia coli.

Authors:  A Dalhoff
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

8.  Staphylococcal endocarditis in rabbits treated with a low dose of cloxacillin.

Authors:  V Lorian; O Zak; S Kunz; J Vaxelaire
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  Sub-Inhibitory Concentration of Piperacillin-Tazobactam May be Related to Virulence Properties of Filamentous Escherichia coli.

Authors:  João Paulo Lopes de Andrade; Luiz de Macêdo Farias; João Fernando Gonçalves Ferreira; Oscar Bruna-Romero; Daniele da Glória de Souza; Maria Auxiliadora Roque de Carvalho; Kênia Valéria dos Santos
Journal:  Curr Microbiol       Date:  2015-09-12       Impact factor: 2.188

10.  Salt-induced filamentous growth of a Salmonella strain isolated from blood.

Authors:  S Yoshida; T Udou; Y Mizuguchi; T Tanabe
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.